Genentech, a member of the Roche Group, is set to acquire a portfolio of next-generation CDK inhibitors from Regor Pharmaceuticals for the treatment of breast cancer.
Under the terms of the agreement, Regor will receive an upfront cash payment of $850 million and is eligible to receive additional cash payments based on the achievement of certain predetermined development, regulatory and commercial milestones.
Genentech will be responsible for clinical development, manufacturing and commercialization worldwide. Regor will continue to manage the two ongoing Phase 1 trials to their completion: Regor will also advance its other distinct assets, unrelated to this deal, in oncology, metabolic diseases and auto-immunity.
“Genentech is well-positioned to bring these novel therapeutics to their full potential to benefit patients with breast cancer around the world,” said Xiayang Qiu, Ph.D., founder and CEO of Regor. “We are proud of the strong data we have generated to date. We look forward to bringing more innovative therapies to patients around the world.”
The proposed transaction is expected to close in the fourth quarter of 2024.
